Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Photonamic GmbH & Co. KG

Home Clinical Trial Sponsors and OrganizationsPhotonamic GmbH & Co. KG

Photonamic GmbH & Co. KG

ACTIVE

Eggerstedter Weg 12, Pinneberg, Schleswig-Holstein, Germanywww.photonamic.deSubsidiary11–50 employeesEstablished: 2002-01-01

Part of SBI HOLDINGS, INC.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

18

6 active

Approvals

2

Total approvals

Agencies

2

Regulatory bodies

Founded

2002

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

9

50.0%

Phase 1

2

11.1%

Phase 3

2

11.1%

Trial Status Distribution

Active, not recruiting

6

33.3%

Completed

7

38.9%

Recruiting

3

16.7%

Terminated

2

11.1%

Clinical Trials

Trials sponsored by this organization (18)

Evaluation of the feasibility of PD L 506 for stereotactic interstitial photodynamic therapy (iPDT) in adult patients with newly diagnosed supratentorial IDH wild-type glioblastoma

Active, not recruiting

Jun 202420 participants

PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma

Sep 202117 participants

Evaluation of the feasibility of PD L 506 for stereotactic interstitial photodynamic therapy (iPDT) in adult patients with newly diagnosed supratentorial IDH wild-type glioblastoma

Jan 202020 participants

Evaluation of the suitability of a 5-ALA patch (PD P 506 A, Alacare®) in the photodynamic therapy (PDT) of actinic keratosison the upper extremities

Jul 201822 participants

5-ALA Patch-PDT of Actinic Keratosis on the Upper Extremities

Jul 201822 participants

Evaluation of the Suitability of PD P 506 A in the PDT of Distal Subungual Onychomycosis (DSO) of the Great Toenail.

Jan 201525 participants

Evaluation of the suitability of PD P 506 A in the photodynamic therapy of Distal Subungual Onychomycosis (DSO) of the great toenail.

Dec 201423 participants

Test of 5-ALA-containing patch application and subsequent illumination as therapy of mild to moderate fungal infections of the great toenail.

Active, not recruiting

Oct 201422 participants

Page 1 of 3

Approvals

Approvals by Agency

EMA

European Medicines Agency

1

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

1

Approvals

Recent Approvals

GLIOLAN 30 MG/ML POLVO PARA SOLUCION ORAL

News

No news articles found

On this page

Overview
Clinical Trials18
Approvals2
News

Back to Organizations